Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Opening Session Panel Discussion

Advertisement

Advertisement




Apr
30
Today In Oncology
Patient-Reported Outcomes With Mirvetuximab Soravtansine vs Chemotherapy in Ovarian Cancer
AI-Driven Model For Identifying Cancer Cachexia
Survival Outcomes May Improve When Treatment Is Guided by Using Both Tissue and Liquid Biopsies
Pretrained AI Models Could Help Accurately Diagnose Nonmelanoma Skin Cancers in Resource Limited Settings
Richard Pazdur MD Honored With 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo